WO2011009757A3 - Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel - Google Patents
Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel Download PDFInfo
- Publication number
- WO2011009757A3 WO2011009757A3 PCT/EP2010/060026 EP2010060026W WO2011009757A3 WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3 EP 2010060026 W EP2010060026 W EP 2010060026W WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- defensin
- influence
- human beta
- pigmentation process
- natural pigmentation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne l'utilisation d'au moins une bêta-défensine humaine, de ses analogues ou agents actifs pouvant stimuler une expression de la bêta-défensine humaine, pour influencer le processus de pigmentation naturel de la peau et/ou des phanères.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009027953 | 2009-07-23 | ||
DE102009027953.9 | 2009-07-23 | ||
DE102009044970A DE102009044970A1 (de) | 2009-07-23 | 2009-09-24 | Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses |
DE102009044970.1 | 2009-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011009757A2 WO2011009757A2 (fr) | 2011-01-27 |
WO2011009757A3 true WO2011009757A3 (fr) | 2011-03-31 |
Family
ID=43384052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/060026 WO2011009757A2 (fr) | 2009-07-23 | 2010-07-13 | Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102009044970A1 (fr) |
WO (1) | WO2011009757A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009044970A1 (de) | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses |
EP3120850B1 (fr) * | 2012-12-14 | 2018-11-07 | Unilever N.V. | Niacinamide pour induire la production de peptides antimicrobiens |
RS62981B1 (sr) * | 2014-06-18 | 2022-03-31 | Medicell Technologies Llc | Kompozicije i postupci za stimulaciju matičnih ćelija |
DK3389620T3 (da) * | 2015-12-15 | 2022-12-19 | Medicell Tech Llc | Stamcellestimulerende sammensætninger og fremgangsmåder til behandling af melasma |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103037A2 (fr) * | 2005-03-29 | 2006-10-05 | Henkel Kommanditgesellschaft Auf Aktien | Composition contenant la $g(b)-defensine 2 |
WO2008028779A1 (fr) * | 2006-09-06 | 2008-03-13 | Henkel Ag & Co. Kgaa | Procédé de caractérisation moléculaire de cheveux âgés |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3725030A1 (de) | 1987-07-29 | 1989-02-09 | Henkel Kgaa | Oberflaechenaktive hydroxysulfonate |
US5136093A (en) | 1991-02-06 | 1992-08-04 | Smith Ronald J | Quaternized panthenol compounds and their use |
DE4413686C2 (de) | 1994-04-20 | 1996-10-24 | Henkel Kgaa | Kationische Zuckertenside, Verfahren zu ihrer Herstellung und deren Verwendung |
FR2843125B1 (fr) | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
DE102009044970A1 (de) | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses |
-
2009
- 2009-09-24 DE DE102009044970A patent/DE102009044970A1/de not_active Withdrawn
-
2010
- 2010-07-13 WO PCT/EP2010/060026 patent/WO2011009757A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103037A2 (fr) * | 2005-03-29 | 2006-10-05 | Henkel Kommanditgesellschaft Auf Aktien | Composition contenant la $g(b)-defensine 2 |
WO2008028779A1 (fr) * | 2006-09-06 | 2008-03-13 | Henkel Ag & Co. Kgaa | Procédé de caractérisation moléculaire de cheveux âgés |
Non-Patent Citations (1)
Title |
---|
CANDILLE SOPHIE I ET AL: "A -defensin mutation causes black coat color in domestic dogs.", SCIENCE (NEW YORK, N.Y.) 30 NOV 2007 LNKD- PUBMED:17947548, vol. 318, no. 5855, 30 November 2007 (2007-11-30), pages 1418 - 1423, XP002610513, ISSN: 1095-9203 * |
Also Published As
Publication number | Publication date |
---|---|
DE102009044970A1 (de) | 2011-01-27 |
WO2011009757A2 (fr) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011009759A3 (fr) | Utilisation de dihydroquercétine et d'au moins un acide aminé pour influencer positivement le processus de pigmentation naturel | |
PL2640352T3 (pl) | Hydrolizat kolagenu do zastosowania do poprawy zdrowia ludzkiej skóry, włosów i/lub paznokci | |
ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
HK1162540A1 (en) | Peptides for use in cosmetic or pharmaceutical treatment of the skin, mucous membranes and/or scalp // | |
ZA201202705B (en) | Peptides used in the treatment and/or care of the skin.mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions | |
FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
IL219318A (en) | 3,5- Dimethoxy-4'-Hydroxystylbenzene (pter) for use in the treatment of diseases, damages or skin injuries and the process of preparing it | |
MX2018004616A (es) | Cosmetica qie tiene bacterias probioticas. | |
EP4272839A3 (fr) | Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine | |
TN2015000520A1 (en) | Pharmaceutical compositions comprising collagen and sodium hyaluronate | |
IL212567A (en) | Zaxanthin, alone or in combination with rutin, spermidine, or both, for the treatment of scalp disorders, use of zaxanthin, alone or in combination with rutin, spermidine or both, for the preparation of a medicinal or cosmetic or nutritional preparation for the treatment of scalp, and a medicinal, cosmetic or nutritional preparation containing Alone or in a mixture with routine, spermidine, or both | |
EP2537513A3 (fr) | Utilisation d'extrait d'Anogeissus pour la production de fibrilline dans la peau | |
EP2274411A4 (fr) | Compositions de xanthohumol et procédés de traitement des maladies ou des affections cutanées | |
WO2015084883A3 (fr) | Compositions et méthodes pour traiter l'arthrose | |
HK1124779A1 (en) | Use of an unsaponifiable extract of plant pulp in the treatment of skin ageing | |
WO2011009757A3 (fr) | Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel | |
WO2011009758A3 (fr) | Utilisation de purine et/ou d'un dérivé de purine et d'au moins un oligonucléotide pour influencer le processus de pigmentation naturel | |
WO2011009763A3 (fr) | Agent cosmétique contenant de la purine et/ou un dérivé de purine et du sclaréol | |
WO2011035945A3 (fr) | Utilisation d'une association de carnitine et/ou d'un dérivé de la carnitine et de purine et/ou d'un dérivé de la purine pour influer sur le processus naturel de pigmentation | |
WO2014045065A3 (fr) | Compositions diététiques et leurs utilisations | |
WO2011009761A3 (fr) | Utilisation de carnitine et de dihydroquercétine pour influencer positivement le processus de pigmentation naturel | |
ZA201804198B (en) | Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body | |
WO2011079971A3 (fr) | Produit cosmétique, contenant euk-134 et/ou euk-118, et au moins une substance traitante | |
EP2404611A4 (fr) | Peptide pour le traitement prophylactique ou thérapeutique de tumeurs de la peau, dans les stades initiaux | |
PT2509944E (pt) | Novos derivados do peróxido, seus processos de preparação e sua utilização em medicina humana e nos cosméticos para tratamento ou prevenção da acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10731524 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10731524 Country of ref document: EP Kind code of ref document: A2 |